Abstract
Viruses and Immunity in Transplant Patients
Highlights
The clinical development of immunosuppressive agents is facilitated by the understanding of the mechanisms of T-cell activation, allowing for the identification of potential new targets and protocols
Virological monitoring of transplant patients has been widely established both for screening transplant patients at risk for virus replication as well as monitoring antiviral treatment responses
Among the members of the Herpesviridae family, human cytomegalovirus (HCMV) is clearly recognized as the major opportunistic agent complicating the outcome of the graft as it may reactivate from latency sites due to antirejection immunosuppressive treatment or be responsible for primary infection in seronegative recipients
Summary
The clinical development of immunosuppressive agents is facilitated by the understanding of the mechanisms of T-cell activation, allowing for the identification of potential new targets and protocols. Viral infections significantly influence the outcome of solid organ and hematopoietic stem cell transplant recipients.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
